

1 **Mutations in DNA polymerase  $\delta$  subunit 1 mediate CMD2-type resistance to**  
2 **Cassava Mosaic Geminiviruses**

3

4 Lim, Y.W.<sup>1,#</sup>, Mansfeld, B.N.<sup>2,#</sup>, Schläpfer, P.<sup>1,#</sup>, Gilbert K.B.<sup>2</sup>, Narayanan, N.N.<sup>2</sup>, Qi, W.<sup>3</sup>,  
5 Wang, Q.<sup>2</sup>, Zhong, Z.<sup>4</sup>, Boyher, A.<sup>2</sup>, Gehan, J.<sup>2</sup>, Beyene, G.<sup>2</sup>, Lin, Z.D.<sup>2</sup>, Esuma. W.<sup>5</sup>, Feng, S.<sup>4</sup>,  
6 Chanez, C.<sup>1</sup>, Eggenberger, N.<sup>1</sup>, Adiga, G.<sup>5</sup>, Alicai, T.<sup>5</sup>, Jacobsen, S.E.<sup>4,6</sup>, Taylor, N.J.<sup>2</sup>, Gruissem,  
7 W.<sup>1,7,\*</sup>, and Bart, R.S.<sup>2,\*</sup>

8

9 Affiliations:

10 <sup>1</sup> Institute of Molecular Plant Biology, Department of Biology, ETH Zürich,  
11 Universitätsstrasse 2, 8092 Zürich, Switzerland.

12 <sup>2</sup> Donald Danforth Plant Science Center, 975 North Warson Road, St. Louis, MO 63132, USA

13 <sup>3</sup> Functional Genomics Center Zurich, ETH Zurich and University of Zurich,  
14 Winterthurerstrasse 190, 8057, Zurich, Switzerland.

15 <sup>4</sup> Department of Molecular, Cell and Developmental Biology, University of California Los  
16 Angeles, Los Angeles, CA, USA

17 <sup>5</sup> Root Crops Program, National Crops Resources Research Institute, P. O. Box 7084,  
18 Kampala, Uganda.

19 <sup>6</sup> Howard Hughes Medical Institute University of California Los Angeles, Los Angeles, CA,  
20 USA.

21 <sup>7</sup> Biotechnology Center, National Chung Hsing University, 145 Xingda Road, Taichung City  
22 40227, Taiwan

23

24 # These authors contributed equally: Lim, Y.W., Mansfeld, B.N., Schläpfer, P.

25 \* Corresponding authors: [wilhelm\\_gruissem@ethz.ch](mailto:wilhelm_gruissem@ethz.ch), [RBart@danforthcenter.org](mailto:RBart@danforthcenter.org)

26 **ABSTRACT**

27 Cassava mosaic disease suppresses cassava yields across the tropics. The dominant *CMD2*  
28 locus confers resistance to the cassava mosaic geminiviruses. It has been reported that *CMD2*-  
29 type landraces lose resistance after regeneration through *de novo* morphogenesis. As full  
30 genome bisulfite sequencing failed to uncover an epigenetic mechanism for loss of resistance,  
31 we performed whole genome sequencing and genetic variant analysis and fine-mapped the  
32 *CMD2* locus to a 190 kilobase interval. Data suggest that *CMD2*-type resistance is caused by  
33 a nonsynonymous, single nucleotide polymorphism in *DNA polymerase  $\delta$  subunit 1*  
34 (*MePOLD1*) located within this region. Virus-induced gene silencing of *MePOLD1* in a Cassava  
35 mosaic disease-susceptible cassava variety produced a recovery phenotype typical of *CMD2*-  
36 type resistance. Analysis of other *CMD2*-type cassava varieties identified additional resistance  
37 alleles within *MePOLD1*. *MePOLD1* resistance alleles represent important genetic resources  
38 for resistance breeding or genome editing, and elucidating mechanisms of resistance to  
39 geminiviruses.

40

## 41 INTRODUCTION

42 Cassava (*Manihot esculenta* Crantz) is a highly heterozygous staple root crop that feeds nearly  
43 a billion people worldwide<sup>1</sup>. Cassava yields are suppressed by infections with cassava mosaic  
44 geminiviruses (CMG, Family *Geminiviridae*: Genus *Begomovirus*) which collectively cause  
45 cassava mosaic disease (CMD). Eleven species of CMG are known to infect cassava across sub-  
46 Saharan Africa, the Indian subcontinent, and recently in several countries of South-East Asia<sup>2</sup>.  
47 CMGs possess two circular single-stranded DNA genomes that are transmitted by the whitefly  
48 *Bemisia tabaci* and spread by farmers who plant infected stem cuttings to establish the next  
49 cropping cycle<sup>3,4</sup>.

50

51 Understanding genetic sources for resistance to geminiviruses is critical to securing yields for  
52 cassava farmers. Three types of resistance to CMGs have been described in cassava as CMD1,  
53 CMD2, and CMD3<sup>5,6</sup>. In all cases the genes responsible for resistance and their modes of  
54 action remain unknown. CMD2-associated resistance, which was discovered in landraces  
55 collected across West Africa, is a dominant single genetic locus located on Chromosome 12<sup>7-</sup>  
56 <sup>10</sup>. We reported previously that CMD2-type resistance is lost when plants are regenerated  
57 through *de novo* morphogenesis in tissue culture<sup>11</sup> (Fig. 1a). While loss of CMD2 resistance  
58 (LCR) occurs consistently in this manner in multiple landraces, LCR was not observed in  
59 varieties developed through breeding programs<sup>12</sup>. Epigenetic somaclonal variation is well  
60 known to produce phenotypic changes in plants regenerated from *in vitro* cultures<sup>13,14</sup>. We  
61 hypothesised, therefore, that the LCR phenotype is caused by culture-induced epigenetic  
62 changes at the CMD2 locus. Single-cytosine resolution epigenome-wide association studies  
63 (EWAS) were performed on multiple cassava plant lines, before and after *in vitro*  
64 morphogenesis. While methylation changes were found across the genome, no consistent  
65 methylation changes were observed within the CMD2 locus (Supplementary Fig. 1,  
66 Supplementary Table 1).

67

68 We therefore investigated the relationship between the CMD2 and LCR phenotypes by  
69 generating three large mapping populations derived from tissue culture regenerated, CMD  
70 susceptible plants (TME204-LCR) crossed with resistant varieties heterozygous for CMD2  
71 (NASE14, NASE19, TME14<sup>8,15</sup>). Field phenotyping was performed over two years at a high  
72 CMD pressure location in Uganda, and progeny lines assessed for resistance or susceptibility

73 to CMD (Fig. 1b, Supplementary Data 1). Resistance segregated at 1:1 ratio (Fig. 1b, across all  
74 populations,  $\chi^2$  p-value = 0.59), indicating that the dominant wildtype allele of CMD2 is  
75 sufficient to restore resistance, and that the CMD2 and LCR phenotypes are caused by a single  
76 genetic locus. If LCR results from a somaclonal epiallele, then passage of CMD resistant F<sub>1</sub>  
77 progeny through morphogenesis would result in the LCR phenotype. However, three  
78 independent, resistant F<sub>1</sub> progeny retained resistance through three consecutive cycles of  
79 somatic embryogenesis and plant regeneration, indicating that sexual propagation prevents  
80 LCR from occurring after *de novo* morphogenesis in tissue culture (Supplementary Fig. 2).  
81 These results indicate that the CMD2 and LCR traits have a genomic basis. We postulate that  
82 spontaneous mutation(s) causing CMD2 resistance occurred in the meristems of field grown  
83 West African landraces and became fixed as periclinal chimeras (Supplementary Fig. 3). The  
84 subset of mutated cells continued to develop into resistant branches that were then selected  
85 by farmers and maintained through clonal propagation, as is common in other crop species<sup>16–</sup>  
86 <sup>18</sup>. Loss of resistance to CMD would be explained if *de novo* morphogenesis occurs from cell  
87 layers that do not carry the resistance allele. Gametes are typically derived from cells within  
88 the L2 layer of the meristem<sup>19</sup>, thus if L2 cells carried the dominant *CMD2* mutation it would  
89 be transmitted to the next generation in a Mendelian manner. Resulting progeny plants  
90 would not be chimeric for the resistance allele and, as we report here, would not lose  
91 resistance to CMD after morphogenesis (Supplementary Fig. 3).

92

93 We combined whole genome sequencing and genetic variant analysis (WGS-GVA) with fine-  
94 mapping to identify *CMD2* and further understand the LCR trait. WGS-GVA has been used to  
95 understand the genetics behind rare human diseases. Causal variants shared by multiple  
96 individuals or families are revealed by comparison of WGS from sick and healthy  
97 individuals<sup>20,21</sup>. We performed WGS-GVA to identify genetic changes in three CMD resistant  
98 and five susceptible F<sub>1</sub> plants (Supplementary Data 2). A filtering approach (Methods,  
99 Expanded Methods, SNP analysis) identified 405 SNPs segregating with the resistance  
100 phenotype in these individuals (Supplementary Data 3). We hypothesised that if the LCR  
101 phenotype is indeed caused by a mutation within *CMD2*, then susceptible LCR lines should  
102 share variants with susceptible F<sub>1</sub> individuals, while wildtype resistant TME204 would not. Of  
103 the 405 SNPs identified in the resistant F<sub>1</sub> progeny, only one nonsynonymous SNP is  
104 heterozygous in the genome of resistant TME204 and absent in the genome of susceptible

105 TME204-LCR plants. This observation is consistent with the hypothesis that CMD resistance is  
106 a chimeric trait in landraces and that passage through culture-induced embryogenesis leads  
107 to loss of chimerism. The SNP is located in the coding sequence of *MePOLD1*  
108 (Manes.12G077400) and changes valine to leucine (V528L) (Fig. 2a). EWAS confirmed that  
109 *MePOLD1* has no DNA methylation differences in resistant and susceptible genotypes  
110 (Supplementary Fig. 1d).

111

112 We also pursued fine-mapping to pinpoint the CMD2/LCR genomic location. The recently  
113 released haplotype resolved genome assemblies of CMD2-resistant African cultivars TME7<sup>22</sup>  
114 and TME204<sup>23</sup> were leveraged to perform *in silico* bulk segregant analysis (BSA) (based on  
115 Takagi et al (2013)<sup>24</sup> and Mansfeld and Grumet (2018)<sup>25</sup>) to map CMD2 resistance. First, F<sub>1</sub>  
116 progeny were screened in the field in Uganda and genotyped with GBS (Fig. 1b,  
117 Supplementary Data 1). These data co-localize the CMD2/LCR locus with the previously  
118 identified CMD2 locus<sup>9</sup>, placing it on Chromosome12 between 5 and 13 Mb of the TME204  
119 haplotype 1 assembly<sup>23</sup> (Fig. 2b). We identified recombinants within this region using SNP  
120 calls from individual samples, thus narrowing the CMD2/LCR-locus to roughly 300 kb (Fig. 2c,  
121 d). To more accurately fine-map the locus, kompetitive allele specific PCR (KASP) markers  
122 were developed bracketing this region (Fig. 2c-f, Supplementary Fig. 4, and Supplementary  
123 Data 4). Approximately 1,000 F<sub>1</sub> individuals derived from a NASE14×TME204-LCR cross were  
124 genotyped and then phenotyped in the greenhouse (Supplementary Data 5) using a  
125 previously described virus induced gene silencing (VIGS)-based infection assay<sup>26</sup>. We  
126 identified 64 (~6.57 cM) recombinants between markers M1 and M8 and further screened  
127 those individuals using three additional markers (M3, M5, M7). This allowed the identification  
128 of recombinants which narrowed the CMD2/LCR locus to 190 kb, between M3 (8,965,853 bp)  
129 and M7 (9,155,913 bp) in the TME204-hap1 assembly<sup>23</sup> (Fig. 2e,f).

130

131 The marker order in both TME7 and TME204<sup>22,23</sup> assemblies is different than in the AM560-2  
132 v6.1 assembly<sup>27</sup>, suggesting a translocation or assembly error in the region which may have  
133 complicated previous efforts to find *CMD2* (Fig. 2f). The newly defined fine-mapped locus  
134 consists of eight annotated genes, including several peroxidase genes that were previously  
135 proposed as *CMD2* candidate genes<sup>9,10,28</sup> and *MePOLD1* (Fig. 2f). Differential gene expression  
136 analyses between susceptible and resistant individuals revealed no significant differences for

137 genes found within this region (Supplementary Fig. 5). Nucleotide level comparison of WGS  
138 data revealed that the V528L SNP in *MePOLD1* was the only genetic change between these  
139 recombinant lines.

140

141 Taken together, these data suggest that variation within the *MePOLD1* CDS underlie CMD2-  
142 type resistance. Finding a nonsynonymous SNP by WGS-GVA in the precisely mapped CMD2  
143 locus by chance is statistically improbable ( $P = 6.1 \times 10^{-4}$ , Monte Carlo simulation,  $n = 100,000$ ).  
144 Components of the DNA polymerase complex have been reported previously as required for  
145 susceptibility to geminiviruses<sup>29–33</sup>. To understand if this holds true for cassava, we targeted  
146 *MePOLD1* for downregulation in the CMD-susceptible cassava variety 60444 using VIGS  
147 (*MePOLD1*-VIGS)<sup>34</sup>. After inoculation with *MePOLD1*-VIGS, only 25% ( $n = 40$ ) of 60444 plants  
148 showed symptoms of infection compared to plants infected with *GUS*-VIGS (76.7%,  $n = 30$ )  
149 and *African cassava mosaic virus* (ACMV) (100%,  $n = 15$ ). CMD symptom severity after  
150 *MePOLD1*-VIGS was also reduced in infected plants of 60444 (Hypergeometric Test,  $P < 0.05$ ,  
151  $n = 40$ , Fig. 3 a,b) and virus titre was significantly lower when compared to plants inoculated  
152 with control VIGS constructs or unmodified ACMV (Fig. 3c). Importantly, plants of 60444 that  
153 displayed CMD symptoms after inoculation with *MePOLD1*-VIGS underwent a recovery  
154 phenotype typical of CMD2 resistance and atypical for this highly CMD-susceptible variety  
155 (Fig. 3d). While the phenotypic result of *MePOLD1*-VIGS was clear, we did not observe a  
156 significant downregulation of *MePOLD1* mRNA levels in 60444 inoculated with *MePOLD1*-  
157 VIGS vectors (Supplementary Fig. 6). This may be because *MePOLD1* is already expressed at  
158 very low levels in leaf tissues (Supplementary Fig. 7<sup>35</sup>), or reflect inherent complexity  
159 associated with using a viral vector to down-regulate a gene required for virus replication  
160 (Supplementary Fig. 8). A significant reduction in *Tomato yellow leaf curl virus* (TYLCV)  
161 accumulation in *Nicotiana benthamiana* was also observed after POLD was downregulated by  
162 *Tobacco rattle virus* (TRV)-mediated VIGS<sup>31</sup>. Since TRV is an RNA virus that replicates via a  
163 double-strand RNA intermediate, downregulating POLD with TRV-VIGS will not reduce VIGS-  
164 mediated siRNA production because TRV is not dependent on POLD for its replication.  
165 Together, our results demonstrate that *MePOLD1*-VIGS is sufficient to provide CMD  
166 resistance, although further work is necessary to understand why a RNAi-mediated  
167 downregulation of *MePOLD1* expression was not observed.

168

169 We next investigated the *MePOLD1* coding sequence of additional CMD-resistant cultivars  
170 using WGS-GVA and/or Sanger sequencing (Fig. 4, Supplementary Data 6). The V528L allele  
171 present in TME204 was also observed in TME419 (Fig. 4), consistent with these landraces  
172 being closely related, and both collected from farmers' fields in Togo/Benin<sup>36,36</sup>. While other  
173 resistant varieties did not contain the V528L allele, two additional nonsynonymous SNPs were  
174 identified within *MePOLD1* (G680V in TME3, TME8, TME14, NASE12 and NASE14 and L685F  
175 in TMS-9102324) (Fig. 4, Supplementary Fig. 9). These results suggest that several distinct  
176 *MePOLD1* alleles may explain CMD2 resistance. We also queried publicly available re-  
177 sequencing data of diverse cassava germplasm<sup>27,37</sup> and cross referenced these varieties for  
178 CMD severity phenotype data available at CassavaBase<sup>38</sup>. Of the 241 accessions with re-  
179 sequencing data, 153 have associated CMD susceptibility scores. *MePOLD1* SNPs were  
180 identified in 94 of the resistant accessions (CMD score of less than 2 out of 5). Specifically, 6,  
181 52, and 36 accessions harbour V528L, G680V, or L685F, respectively. (Fig. 4b). Analysis of the  
182 remaining 59 varieties identified three additional nonsynonymous SNPs in *MePOLD1*, unique  
183 to accessions with CMD severity scores below 2: L598W, G680R, and A684G; found in 17, 2,  
184 and 4 samples, respectively (Fig. 4c). In every case, across 117 samples in which POLD1  
185 variants were identified, the putative resistance allele is observed in the heterozygous  
186 context, suggesting that these amino acid changes might be deleterious if homozygous.  
187 Indeed, an EMS mutant in *Arabidopsis* POLD1 (at position A684 in *MePOLD1*; Fig. 4c) is  
188 hypomorphic and lethal at 28°C<sup>39</sup>. Five of the six mutations identified in *MePOLD1* (V528L,  
189 G680V, G680R, A684G, L685F) are immediately adjacent to the R696-E539 (*MePOLD1*: R681-  
190 E524) salt bridge between the finger and N-terminal domains described in yeast POLD (Fig.  
191 4d, e). Mutations disrupting this salt bridge have been shown to result in decreased  
192 polymerase activity and fidelity<sup>40,41</sup>. Furthermore, a homozygous R696W mutation is lethal in  
193 yeast and is associated with oncogenesis in humans<sup>41</sup>.

194

195 The above data suggest a model wherein *MePOLD1* is a susceptibility factor involved in  
196 cassava geminivirus replication and that nonsynonymous mutations within *MePOLD1* lead to  
197 CMD2-type resistance. We applied this model to an unexplained observation. The resistant  
198 NASE14 parent from the mapping populations is heterozygous for the G680V mutation.  
199 NASE14 (the line formerly known as MM96/4271) was developed by crossing in a breeding  
200 program at the International Institute for Tropical Agriculture<sup>42</sup> and does not lose resistance



201 after passage through culture-induced morphogenesis<sup>12</sup>. However, we previously reported  
202 an exception: in experiments where NASE14 was used to generate transgenic lines all but one  
203 of the transgenic events remained resistant to CMD<sup>43</sup>. To understand this unexpected  
204 outcome, targeted Sanger sequencing of *MePoLD1* was performed on the transgenic line  
205 5001-NASE14-#41 that had lost CMD2 resistance. The result confirmed that this line retained  
206 the heterozygous G680V mutation characteristic of the resistant NASE14 cultivar. However,  
207 examining the cloned, full length CDS revealed the presence of an additional heterozygous  
208 SNP not present in WT NASE14. This new SNP introduces a premature stop codon at amino  
209 acid position 574 within the resistance allele (Supplementary Fig. 10). Thus, transgenic event  
210 5001-NASE14-#41 contains a susceptible version of *MePoLD1*, but lacks its original functional  
211 resistance allele, which would explain its acquired susceptibility to infection by CMGs. This  
212 spontaneous knock-out of the resistance allele provides further strong evidence that  
213 mutations in *MePoLD1* explain CMD2 type resistance in cassava.

214

215 Collectively, our data indicate that amino acid changes near the active centre of MePoLD1  
216 cause the dominant CMD2-type resistance. Several dominant resistance genes for plant  
217 viruses have been reported, most of which belong to the NBS-LRR class of proteins<sup>44</sup>.  
218 MePoLD1 represents an unexpected, novel type of resistance protein in plants. Evidence  
219 suggests that this has been selected as a chimeric clonal variant multiple times by West  
220 African farmers, and due to its monogenic, dominant nature is now favoured in breeding  
221 programs in Africa, India, and South-East Asia<sup>8</sup>. Mutations in POLD predispose humans and  
222 mice to a range of cancers, especially mutations that specifically affect the proofreading  
223 activity or dNTP selectivity of the enzyme<sup>45</sup>. It is possible that the identified mutations in  
224 *MePoLD1* may similarly introduce replication errors in the geminiviruses, which would impair  
225 their replication efficacy and thereby reduce virus load in the host plant. This hypothesis is  
226 supported by the co-localization of MePoLD1 mutations to those in yeast and humans known  
227 to decrease DNA replication activity, and accuracy<sup>40,41,45</sup>. We cannot exclude, however, that  
228 the *MePoLD1* mutations weaken or block interactions with the virus replication-enhancer  
229 protein AC3, which interacts with subunits of POLD<sup>31</sup>. CMD2 resistance has remained robust  
230 in farmers' fields over at least two decades. However, some caution for overreliance on CMD2  
231 is presented here with evidence that yields and livelihoods for millions of cassava farmers are  
232 being secured by a few SNPs in one gene. The identification of mutations in *MePoLD1* as the



233 cause for CMD2-type resistance will facilitate the production of CMD resistant cassava  
234 varieties by SNP-assisted breeding or genome editing to introduce the identified SNPs into  
235 susceptible cultivars and provides opportunity to further elucidate mechanisms of resistance  
236 to geminiviruses.

237

## 238 **METHODS (see Supplementary File 1 for expanded methods section)**

### 239 **Plant lines, mapping populations and disease scoring**

240 For detailed descriptions of each plant line used in this study, see Supplementary  
241 Table 1 and Supplementary Data 1 and 2. TME204-LCR was described previously<sup>46</sup>.

242 A crossing program was conducted in Uganda during the 2017/2018 cropping season  
243 to perform controlled crosses between CMD susceptible cultivar TME204-LCR and three  
244 CMD resistant wildtype cassava varieties (TME14, NASE14, NASE19) following the standard  
245 procedures described by Kawano (1980)<sup>47</sup> and Hahn et al (1980)<sup>48</sup>. During the pollination  
246 period, special care was taken to cover mature flowers with pollination bags 2-3 days before  
247 and after pollination. A total of 7,200 botanical seeds were harvested from mature fruits  
248 within three months after pollination and stored in paper bags for approximately three  
249 weeks to break dormancy. All seeds were planted in field-conditioned nursery beds and  
250 4,300 resultant seedlings transplanted to a field at six weeks or age and allowed to grow  
251 under natural field conditions for 12 months. The field trials were conducted at Namulonge,  
252 central Uganda, which is a hotspot for cassava mosaic disease with high whitefly vector  
253 populations. CMD-symptomatic plants of local cultivar Bao were planted as spreader rows  
254 to augment field inoculation of CMGs. To achieve phenotyping, monthly CMD severity was  
255 scores (starting from 1 month after transplanting seedlings) were recorded on a 1-5 scale<sup>49</sup>  
256 where: 1 = no symptoms; 2 = mild chlorotic pattern over the entire leaf although the leaf  
257 appears green and healthy; 3 = moderate mosaic pattern throughout the leaf, narrowing  
258 and distortion in the lower one-third of leaflets; 4 = severe mosaic, distortion in two-thirds  
259 of the leaflets and general reduction in leaf size; and 5 = severe mosaic distortion in the  
260 entire leaf. The final CMD severity data recorded at the crop age of 11 months were used  
261 for subsequent analyses.

262 A similar crossing program was established at Kandara, Kenya in which TME204-LCR  
263 was crossed with the two CMD resistant wildtype cassava varieties (TME14 and NASE14).  
264 Resulting seeds were collected and shipped to DDPSC, St Louis, USA.

265

### 266 **Epigenome-Wide Association Studies (EWAS)**

267 Whole genome methylation of TME7 and TME204 background samples were  
268 prepared with Bisulfite Kit (Qiagen, Germantown, Maryland, USA) and enzymatic Methyl-Seq  
269 kit (New England BioLabs, Ipswich, Massachusetts, USA), respectively. For more information  
270 on library preparation see expanded methods (Supplementary File 1). DNA methylation level  
271 at each cytosine was calculated by number of methylated C vs. total C and T count.  
272 Differentially Methylated Cytosines (DMCs) were identified by methdiff.py in BSMAP<sup>50</sup> where  
273 differences in CG, CHG, and CHH methylation were at least 0.3, 0.2, and 0.1, respectively.  
274 Methylation levels of DMCs of each sample versus three TME7 and one TME204 wildtype  
275 were merged as a consensus DMCs table. Methylation levels of each sample in DMCs table  
276 were subjected to one-way ANOVA test by comparing seven resistant vs. seven susceptible  
277 samples to calculate p-value of each DMC. Manhattan plot of p-value were generated by R  
278 package qqman<sup>51</sup>. Methylation track files were visualised with Integrative Genomics Viewer  
279 (IGV, v3.0)<sup>52</sup>.

280

### 281 **CMD resistance across cycles of somatic embryogenesis**

282 The three CMD resistant F1 progeny lines, NASE14×TME204-LCR.82,  
283 NASE14×TME204-LCR.73 and NASE14×TME204-LCR.16 were established, and micro  
284 propagated in tissue culture. Organised somatic embryos (OES) were induced from leaf  
285 explants and plants regenerated to produce Cycle 1 OES-derived plants<sup>53</sup>. This process was  
286 repeated with Cycle 1 OES plants to produce Cycle 2 OES plants, and again to generate Cycle  
287 3 OES plants for each of the F1 progeny lines. Regenerated plants were established in the  
288 greenhouse<sup>53</sup> and inoculated with *East African cassava mosaic virus* (EACMV-KE2) isolate  
289 K201 as described previously<sup>26</sup>. Ten plants were inoculated from each cycle of OES-derived  
290 plants for all three progeny and assessed for development of CMD leaf symptoms over a  
291 period of 90 days using a 0-5 visual scoring method<sup>54</sup>. At 51 days after inoculation plants were  
292 ratooned (cut back) and a new round of CMD symptoms scored on leaves produced by shoot  
293 regrowth to confirm the original phenotype.

294

## 295 **Whole genome sequencing and genomic variant analysis**

296 Illumina sequencing: Leaf material was collected from 42 cassava genotypes and FEC  
297 material from two cassava genotypes (Supplementary Data 2) for whole genome Illumina  
298 sequencing (see Expanded Methods). DNA libraries were prepared using the Illumina TruSeq  
299 Nano DNA High Throughput Library Prep Kit (20015965, Illumina, San Diego, California, USA).  
300 Libraries were sequenced using an Illumina NovaSeq system for 2 × 151 cycles. On average  
301 100X Illumina paired-end (PE) data were collected per sample.

302 Pre-processing and mapping of reads was performed using ezRun  
303 (<https://github.com/uzh/ezRun>) in combination with SUSHI<sup>55</sup>. Technical quality was  
304 evaluated using FastQC (v0.11.7). Possible contaminations were screened using FastqScreen  
305 (v0.11.1) against customised databases (See Expanded Methods). Reads were pre-processed  
306 using fastp (v0.20.0) and aligned to the *Manihot esculenta* TME204 genome (V1.0, FGCZ)  
307 using Bowtie2 (v2.3.2) with the “--very-sensitive” option. PCR-duplicates were marked using  
308 Picard (v2.9.0). Frequency-based calls for all variants with allele frequency above 20% were  
309 performed with freebayes-parallel (v1.2.0-4-gd15209e). Relatedness analysis of SNPs using  
310 identity-by-descent (IBD) measures, was performed using the R/Bioconductor Package  
311 SNPRelate (v 3.13).

312 SNP analysis: To find potential SNPs, a custom python script  
313 ([https://github.com/pascalschlaepferprivate/filter\\_vcf](https://github.com/pascalschlaepferprivate/filter_vcf)) parses the VCF file produced by  
314 freebayes, computes total coverage of the SNP, and then absolute and relative read coverage  
315 of all SNP variants. Samples were organized as ingroup (genotypes that show a SNP variant of  
316 interest), outgroup (genotypes that do not show SNP variant of interest), facultative ingroup  
317 (genotypes that may show SNP variant of interest), and facultative outgroup (genotypes that  
318 may not show SNP variant of interest), and SNPs were filtered according to these groups and  
319 additional parameters (see expanded methods in Supplementary File 1).

320

## 321 **Genetic mapping**

322 Genotyping by Sequencing and *in silico* bulk segregant analysis: Approximately 1,300  
323 individual F<sub>1</sub> progeny and the parental lines from the NASE14xTME204-LCR population  
324 generated in Kenya were characterised with genotyping-by-sequencing (GBS) at UW-Madison  
325 Biotechnology Center following their standard ApeKI restriction enzyme protocol. Reads of

326 100bp were demultiplexed<sup>56</sup> and mapped<sup>57</sup> to the TME204 hap1 assembly<sup>23</sup>. SNPs were called  
327 using GATK4<sup>58,59</sup> and quality filtered SNPs that were heterozygous in both parents retained  
328 using vcftools v0.1.14<sup>60</sup>. Using the field phenotypes, a random subset of the most CMD  
329 resistant and most susceptible lines was selected as the resistant and susceptible bulks (n =  
330 125 each), respectively, to perform *in silico* bulk segregant analysis using the QTLseqr  
331 package<sup>25</sup>.

332 Fine-mapping using GBS and KASP markers: To further narrow the CMD2 locus,  
333 individual F<sub>1</sub> progeny were analysed for recombination events within the defined locus (~5-  
334 13Mb). While mapping in outcrossers using F<sub>1</sub> populations is established, mapping in this  
335 population is complicated by the TME204-LCR parent in that heterozygous progeny can be  
336 either resistant or susceptible. Thus, only recombinants with a genotype-phenotype  
337 mismatch were selected as informative. For example, in a phenotypically resistant F<sub>1</sub> line with  
338 a recombination that transitions from genetically heterozygous to genetically homozygous  
339 susceptible, one can exclude the homozygous susceptible region as not carrying *CMD2*. Six  
340 resistant and six susceptible recombinant individuals were identified with such recombination  
341 within the broad CMD2 locus and were used to exclude genomic regions in which at least two  
342 lines supported such exclusion. The narrow locus defined by GBS (Chromosome12: 8,976,221-  
343 9,314,764) was used to design KASP markers (Supplementary Data 4) spanning 1.5 Mb  
344 bracketing this region. Additional recombinants were sought in a similar manner within a  
345 second ~1000 individual population using highly accurate genotyping and phenotyping assays  
346 (KASP-marker-based assay combined with phenotyping with a VIGS based approach<sup>26</sup>). All  
347 recombinants were sequenced using Illumina WGS data and nucleotide level comparison was  
348 performed by alignment to TME7<sup>22</sup> and TME204<sup>23</sup> assemblies and manual inspection using  
349 CLC Genomics and IGV<sup>52</sup>.

350 Phenotyping for fine-mapping: F<sub>1</sub> progeny seeds were germinated in a growth  
351 chamber at DDPSC, transferred to the greenhouse and inoculated with a virus-induced-gene-  
352 silencing version of *East African cassava mosaic virus* K201 (SPINDLY-VIGS), as described by  
353 Beyene et al. (2017). Plants were assessed over a four-week period. Plants which died were  
354 scored as CMD susceptible while those that recovered from initial symptoms and re-  
355 established healthy growth were scored as CMD resistant.

356

357 **RNAseq analysis**

358 For differential expression analysis, first a transcriptome fasta of the spliced exons was  
359 made from the TME204-hap1 gff file using ‘gffread -w’ from the cufflinks package<sup>61</sup>. This  
360 transcriptome was then concatenated to the whole genome to prepare an alignment decoy  
361 file and index using the commands here [https://combine-lab.github.io/alevin-](https://combine-lab.github.io/alevin-tutorial/2019/selective-alignment/)  
362 [tutorial/2019/selective-alignment/](https://combine-lab.github.io/alevin-tutorial/2019/selective-alignment/). Trimmed RNAseq reads were then pseudo-aligned to the  
363 TME204-hap1 transcriptome using Salmon v1.5.2 default settings<sup>62</sup>. Read count data was  
364 imported into R using the tximport package<sup>63</sup>. Samples were then defined as resistant or  
365 susceptible and differential expression on the integer count values was performed using  
366 DESeq2<sup>64</sup>. Genes with a sum of less than 50 reads across all samples were excluded from  
367 analysis. Differential expression was performed using “apeglm” as the Log Fold Change  
368 Shrinkage method<sup>65</sup>. Genes were defined as being significantly differentially expressed if they  
369 had an adjusted p-value<sup>66</sup> of less than 0.05. Normalised counts were plotted using ggplot and  
370 tidyverse<sup>67</sup> functions in R.

371

### 372 **VIGS targeting of *MePOLD1***

373 A VIGS approach was designed and performed based on Lentz et al. (2019)<sup>34</sup>. A 400 bp  
374 coding sequence of *MePOLD1* (position 438-837, corresponding to 8905774-8905965 of  
375 chr12 in AM560 v8, 9076083-9076741 of chr12 in TME204 hap1) as synthesised (Twist  
376 Biosciences, California, USA) and inserted in the multiple cloning site of the ACMV-based VIGS  
377 vector using KpnI and SpeI. The 400 bp coding sequence is conserved in MePOLD1 of 60444,  
378 TME3, TME204 and AM560 and n-mers (18 – 24 nt) were checked against the cassava AM560  
379 v6.1 genome sequence with SGN VIGS from Sol Genomics (<https://vigs.solgenomics.net/>)<sup>38</sup> to  
380 validate that the sequence we used to target MePOLD1 has no off-targets in cassava. The  
381 number of 60444 plants inoculated were  $n = 15$  for ACMV,  $n = 40$  for *MePOLD1*-VIGS,  $n = 30$   
382 for *GUS*-VIGS, and  $n = 15$  for Mock treatments. Leaf symptom scoring was based on Fauquet  
383 and Fargette (1990)<sup>54</sup>. ACMV titre and *MePOLD1* expression were quantified through qPCR  
384 from total DNA and RNA extracted respectively from the top 1-2 leaves harvested at first signs  
385 of CMD symptoms. A Mann-Whitney U test was used to analyse the statistical significance.  
386 Primers are listed in Supplementary Table 2.

387

### 388 **Identification of additional MePOLD1 variants**

389 A publicly available dataset was accessed containing sequencing data of 241 diverse  
390 accessions that identified over 28 million segregating variants<sup>37</sup>. All positions within the  
391 *MePOLD1* gene (AM560-2 v6.1 coordinates) were extracted from the Chromosome12 VCF file  
392 available through the cassavabase.org FTP server (c12.DepthFilt\_phasedSNPs.vcf), and  
393 effects of the variants on the protein coding sequence determined using snpEff<sup>68</sup>. Additional  
394 analysis was done with Sanger sequencing (Supplementary Data 6). Names listed in Fig. 4c are  
395 as listed in Ramu et al.<sup>37</sup> We note that according to this publication, TMS972205 contains a  
396 different SNP than the one identified here and is referred to as TMS-972205.

397

### 398 **POLD1 Protein sequence analyses**

399 The 3D structure of the yeast POLD catalytic subunit and template DNA (PDB ID: 3IAY,  
400 Swan et al., 2009), was visualised in ChimeraX<sup>69</sup>. The N-terminal domain, exonuclease  
401 domain, and finger, palm, and thumb motifs from Swan et al., 2009<sup>70</sup> were colour-coded and  
402 the residues corresponding to the nonsynonymous mutations identified across the cassava  
403 varieties are highlighted.

404

### 405 **Analysis of *MePOLD1* in 5001-NASE 14-#41**

406 The full-length cDNA of *MePOLD1* was amplified from cassava plant line 5001-NASE 14-#41<sup>43</sup>.  
407 Primers were designed to be specific for the haplotype carrying the resistance *MePOLD1* allele  
408 and PCR performed. The PCR product was cloned into the binary vector pCAMBIA1305.1 using  
409 the In-Fusion<sup>®</sup> HD Cloning Kit (Takara Bio USA, Inc.) and the resulting clones sequenced by  
410 Sanger sequencing. Primers are listed in Supplementary Table 2.

411

### 412 **DATA AVAILABILITY**

413 Source data are provided with this paper as Supplementary Datasets. Raw bisulfite sequence  
414 data is available through NCBI GEO (GSE192748 data will be made public before publication).  
415 Whole Genome Sequencing and RNAseq raw read data can be accessed at NCBI  
416 (<https://www.ncbi.nlm.nih.gov/bioproject/PRJNA787456>;

417 Reviewer link: [https://dataview.ncbi.nlm.nih.gov/object/PRJNA787456?reviewer=r6e2b80b](https://dataview.ncbi.nlm.nih.gov/object/PRJNA787456?reviewer=r6e2b80b8055v1lcugaa2q51lh)  
418 [8055v1lcugaa2q51lh](https://dataview.ncbi.nlm.nih.gov/object/PRJNA787456?reviewer=r6e2b80b8055v1lcugaa2q51lh)).

419

### 420 **CODE AVAILABILITY**

421 Scripts used to generate figures are deposited in github and in the Supplementary Data  
422 available with this publication.

423

## 424 REFERENCES

- 425 1. Food and Agriculture Organization of the United Nations. *Save and Grow: A*  
426 *Policymaker's Guide to Sustainable Intensification of Smallholder Crop Production*.  
427 (Food & Agriculture Org., 2018).
- 428 2. Uke, A. *et al.* Cassava mosaic disease and its management in Southeast Asia. *Plant*  
429 *Mol. Biol.* (2021) doi:10.1007/s11103-021-01168-2.
- 430 3. Ephraim, N., Yona, B., Evans, A., Sharon, A. & Titus, A. Effect of cassava brown streak  
431 disease (CBSD) on cassava (*Manihot esculenta* Crantz) root storage components,  
432 starch quantities and starch quality properties. *International Journal of Plant Physiology*  
433 *and Biochemistry* **7**, 12–22 (2015).
- 434 4. McCallum, E. J., Anjanappa, R. B. & Gruissem, W. Tackling agriculturally relevant  
435 diseases in the staple crop cassava (*Manihot esculenta*). *Curr. Opin. Plant Biol.* **38**, 50–  
436 58 (2017).
- 437 5. Akano, O., Dixon, O., Mba, C., Barrera, E. & Fregene, M. Genetic mapping of a  
438 dominant gene conferring resistance to cassava mosaic disease. *Theor. Appl. Genet.*  
439 **105**, 521–525 (2002).
- 440 6. Okogbenin, E. *et al.* Molecular marker analysis and validation of resistance to cassava  
441 mosaic disease in elite cassava genotypes in Nigeria. *Crop Sci.* **52**, 2576–2586 (2012).
- 442 7. Moreno, I., Tomkins, J., Okogbenin, E. & Fregene, M. Progress in positional cloning of  
443 CMD2 the gene that confers high level of resistance to the Cassava Mosaic Disease  
444 (CMD). *J. Insect Sci.* **8**, (2008).
- 445 8. Rabbi, I. Y. *et al.* High-resolution mapping of resistance to cassava mosaic  
446 geminiviruses in cassava using genotyping-by-sequencing and its implications for  
447 breeding. *Virus Res.* **186**, 87–96 (2014).



- 448 9. Rabbi, I. Y. *et al.* Genome-wide association analysis reveals new insights into the  
449 genetic architecture of defensive, agro-morphological and quality-related traits in  
450 cassava. *Plant Mol. Biol.* (2020) doi:10.1007/s11103-020-01038-3.
- 451 10. Wolfe, M. D. *et al.* Genome-Wide Association and Prediction Reveals Genetic  
452 Architecture of Cassava Mosaic Disease Resistance and Prospects for Rapid Genetic  
453 Improvement. *Plant Genome* **9**, (2016).
- 454 11. Beyene, G. *et al.* Loss of CMD2-mediated resistance to cassava mosaic disease in  
455 plants regenerated through somatic embryogenesis: Uniform loss of CMD resistance in  
456 cassava. *Mol. Plant Pathol.* **17**, 1095–1110 (2016).
- 457 12. Chauhan, R. D., Beyene, G. & Taylor, N. J. Multiple morphogenic culture systems  
458 cause loss of resistance to cassava mosaic disease. *BMC Plant Biol.* **18**, 132 (2018).
- 459 13. Ong-Abdullah, M. *et al.* Loss of Karma transposon methylation underlies the mantled  
460 somaclonal variant of oil palm. *Nature* **525**, 533–537 (2015).
- 461 14. Deng, Y. *et al.* Epigenetic regulation of antagonistic receptors confers rice blast  
462 resistance with yield balance. *Science* **355**, 962–965 (2017).
- 463 15. Manze, F. *et al.* Genetic Gains for Yield and Virus Disease Resistance of Cassava  
464 Varieties Developed Over the Last Eight Decades in Uganda. *Front. Plant Sci.* **12**,  
465 651992 (2021).
- 466 16. Satina, S., Blakeslee, A. F. & Avery, A. G. Demonstration of the three germ layers in  
467 the shoot apex of *Datura* by means of induced polyploidy in periclinal chimeras. *Am. J.*  
468 *Bot.* **27**, 895–905 (1940).
- 469 17. Skene, K. G. M. & Barlass, M. Studies on the Fragmented Shoot Apex of Grapevine:  
470 IV. SEPARATION OF PHENOTYPES IN A PERICLINAL CHIMERA IN VITRO. *J. Exp.*  
471 *Bot.* **34**, 1271–1280 (1983).
- 472 18. Ohtsu, Y. & Kuhara, S. Periclinal Chimera of Citrus Resistant to Citrus Canker and  
473 Citrus Tristeza Virus: Chimerism and Composition of Fruit Tissue in the Synthetic  
474 Periclinal Chimeras “FN-1” and “NF-3.” *Japanese Journal of Phytopathology* vol. 60 20–  
475 26 (1994).

- 476 19. Marcotrigiano, M. & Bernatzky, R. Arrangement of cell layers in the shoot apical  
477 meristems of periclinal chimeras influences cell fate. *Plant J.* **7**, 193–202 (1995).
- 478 20. Thaventhiran, J. E. D. *et al.* Whole-genome sequencing of a sporadic primary  
479 immunodeficiency cohort. *Nature* **583**, 90–95 (2020).
- 480 21. Liu, H.-Y. *et al.* Diagnostic and clinical utility of whole genome sequencing in a cohort of  
481 undiagnosed Chinese families with rare diseases. *Sci. Rep.* **9**, 19365 (2019).
- 482 22. Mansfeld, B. N. *et al.* Large structural variations in the haplotype-resolved African  
483 cassava genome. *Plant J.* (2021) doi:10.1111/tpj.15543.
- 484 23. Qi, W. *et al.* The haplotype-resolved chromosome pairs of a heterozygous diploid  
485 African cassava cultivar reveal novel pan-genome and allele-specific transcriptome  
486 features. *Gigascience* **11**, (2022).
- 487 24. Takagi, H. *et al.* QTL-seq: rapid mapping of quantitative trait loci in rice by whole  
488 genome resequencing of DNA from two bulked populations. *The Plant Journal* vol. 74  
489 174–183 (2013).
- 490 25. Mansfeld, B. N. & Grumet, R. QTLseqr: An R package for bulk segregant analysis with  
491 next-generation sequencing. *Plant Genome* **11**, 180006 (2018).
- 492 26. Beyene, G., Chauhan, R. D. & Taylor, N. J. A rapid virus-induced gene silencing (VIGS)  
493 method for assessing resistance and susceptibility to cassava mosaic disease. *Virology* **14**, 47 (2017).
- 494 **14**, 47 (2017).
- 495 27. Bredeson, J. V. *et al.* Sequencing wild and cultivated cassava and related species  
496 reveals extensive interspecific hybridization and genetic diversity. *Nat. Biotechnol.* **34**,  
497 562–570 (2016).
- 498 28. Kuon, J.-E. *et al.* Haplotype-resolved genomes of geminivirus-resistant and  
499 geminivirus-susceptible African cassava cultivars. *BMC Biol.* **17**, 75 (2019).
- 500 29. Maio, F. *et al.* Identification of Tomato Proteins That Interact With Replication Initiator  
501 Protein (Rep) of the Geminivirus TYLCV. *Front. Plant Sci.* **11**, 1069 (2020).
- 502 30. Gutiérrez, L. *et al.* Multi-environment multi-QTL association mapping identifies disease  
503 resistance QTL in barley germplasm from Latin America. *Theor. Appl. Genet.* **128**, 501–

- 504 516 (2015).
- 505 31. Wu, M. *et al.* Plant DNA polymerases  $\alpha$  and  $\delta$  mediate replication of geminiviruses. *Nat.*  
506 *Commun.* **12**, 2780 (2021).
- 507 32. Hanley-Bowdoin, L., Settlage, S. B. & Robertson, D. Reprogramming plant gene  
508 expression: a prerequisite to geminivirus DNA replication. *Mol. Plant Pathol.* **5**, 149–156  
509 (2004).
- 510 33. Hanley-Bowdoin, L., Bejarano, E. R., Robertson, D. & Mansoor, S. Geminiviruses:  
511 masters at redirecting and reprogramming plant processes. *Nat. Rev. Microbiol.* **11**,  
512 777–788 (2013).
- 513 34. Lentz, E. M. *et al.* Cassava geminivirus agroclones for virus-induced gene silencing in  
514 cassava leaves and roots. *Plant Methods* **14**, 73 (2018).
- 515 35. Wilson, M. C. *et al.* Gene expression atlas for the food security crop cassava. *New*  
516 *Phytol.* **213**, 1632–1641 (2017).
- 517 36. Raji, A. A. *et al.* Gene-based microsatellites for cassava (*Manihot esculenta* Crantz):  
518 prevalence, polymorphisms, and cross-taxa utility. *BMC Plant Biol.* **9**, 118 (2009).
- 519 37. Ramu, P. *et al.* Cassava haplotype map highlights fixation of deleterious mutations  
520 during clonal propagation. *Nat. Genet.* **49**, 959–963 (2017).
- 521 38. Fernandez-Pozo, N. *et al.* The Sol Genomics Network (SGN)--from genotype to  
522 phenotype to breeding. *Nucleic Acids Res.* **43**, D1036-41 (2015).
- 523 39. Iglesias, F. M. *et al.* The arabidopsis DNA polymerase  $\delta$  has a role in the deposition of  
524 transcriptionally active epigenetic marks, development and flowering. *PLoS Genet.* **11**,  
525 e1004975 (2015).
- 526 40. Foley, M. C., Couto, L., Rauf, S. & Boyke, A. Insights into DNA polymerase  $\delta$ 's  
527 mechanism for accurate DNA replication. *J. Mol. Model.* **25**, 80 (2019).
- 528 41. Dae, D. L., Mertz, T. M. & Shcherbakova, P. V. A cancer-associated DNA polymerase  
529  $\delta$  variant modeled in yeast causes a catastrophic increase in genomic instability. *Proc.*  
530 *Natl. Acad. Sci. U. S. A.* **107**, 157–162 (2010).
- 531 42. Mukiibi, D. R. *et al.* Resistance of advanced cassava breeding clones to infection by

- 532 major viruses in Uganda. *Crop Prot.* **115**, 104–112 (2019).
- 533 43. Narayanan, N., Beyene, G., Chauhan, R. D., Grusak, M. A. & Taylor, N. J. Stacking  
534 disease resistance and mineral biofortification in cassava varieties to enhance yields  
535 and consumer health. *Plant Biotechnol. J.* **19**, 844–854 (2021).
- 536 44. de Ronde, D., Butterbach, P. & Kormelink, R. Dominant resistance against plant  
537 viruses. *Front. Plant Sci.* **5**, 307 (2014).
- 538 45. Fuchs, J., Cheblal, A. & Gasser, S. M. Underappreciated Roles of DNA Polymerase  $\delta$   
539 in Replication Stress Survival. *Trends Genet.* **37**, 476–487 (2021).
- 540 46. Wagaba, H. *et al.* Field Level RNAi-Mediated Resistance to Cassava Brown Streak  
541 Disease across Multiple Cropping Cycles and Diverse East African Agro-Ecological  
542 Locations. *Front. Plant Sci.* **7**, 2060 (2016).
- 543 47. Kawano, K. *Hybridisation of Crop Plants*. (American Society of Agronomy and Crop  
544 Science Society of America, 1980).
- 545 48. Hahn, S. K., Terry, E. R. & Leuschner, K. Breeding cassava for resistance to cassava  
546 mosaic disease. *Euphytica* **29**, 673–683 (1980).
- 547 49. International Institute of Tropical Agriculture (IITA). *Cassava in Tropical Africa: A*  
548 *Reference Manual*. (1990).
- 549 50. Xi, Y. & Li, W. BSMAP: whole genome bisulfite sequence MAPping program. *BMC*  
550 *Bioinformatics* **10**, 232 (2009).
- 551 51. D. Turner, S. qqman: an R package for visualizing GWAS results using Q-Q and  
552 manhattan plots. *J. Open Source Softw.* **3**, 731 (2018).
- 553 52. Robinson, J. T. *et al.* Integrative genomics viewer. *Nat. Biotechnol.* **29**, 24–26 (2011).
- 554 53. Taylor, N. *et al.* A high-throughput platform for the production and analysis of transgenic  
555 cassava (*Manihot esculenta*) plants. *Trop. Plant Biol.* **5**, 127–139 (2012).
- 556 54. Fauquet, C. African cassava mosaic virus: Etiology, epidemiology, and control. *Plant*  
557 *Dis.* **74**, 404 (1990).
- 558 55. Hatakeyama, M. *et al.* SUSHI: an exquisite recipe for fully documented, reproducible  
559 and reusable NGS data analysis. *BMC Bioinformatics* **17**, 228 (2016).

- 560 56. Herten, K., Hestand, M. S., Vermeesch, J. R. & Van Houdt, J. K. J. GBSX: a toolkit for  
561 experimental design and demultiplexing genotyping by sequencing experiments. *BMC*  
562 *Bioinformatics* **16**, 73 (2015).
- 563 57. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler  
564 transform. *Bioinformatics* **25**, 1754–1760 (2009).
- 565 58. Van der Auwera, G. A. *et al.* From FastQ data to high confidence variant calls: the  
566 Genome Analysis Toolkit best practices pipeline. *Curr. Protoc. Bioinformatics* **43**,  
567 11.10.1-11.10.33 (2013).
- 568 59. Van der Auwera, G. A. & O'Connor, B. D. *Genomics in the Cloud: Using Docker, GATK,*  
569 *and WDL in Terra.* ("O'Reilly Media, Inc.," 2020).
- 570 60. Danecek, P. *et al.* The variant call format and VCFtools. *Bioinformatics* **27**, 2156–2158  
571 (2011).
- 572 61. Trapnell, C. *et al.* Transcript assembly and quantification by RNA-Seq reveals  
573 unannotated transcripts and isoform switching during cell differentiation. *Nat.*  
574 *Biotechnol.* **28**, 511–515 (2010).
- 575 62. Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast  
576 and bias-aware quantification of transcript expression. *Nat. Methods* **14**, 417–419  
577 (2017).
- 578 63. Sonesson, C., Love, M. I. & Robinson, M. D. Differential analyses for RNA-seq:  
579 transcript-level estimates improve gene-level inferences. *F1000Res.* **4**, 1521 (2015).
- 580 64. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and  
581 dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
- 582 65. Zhu, A., Ibrahim, J. G. & Love, M. I. Heavy-tailed prior distributions for sequence count  
583 data: removing the noise and preserving large differences. *Bioinformatics* **35**, 2084–  
584 2092 (2019).
- 585 66. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and  
586 powerful approach to multiple testing. *J. R. Stat. Soc.* **57**, 289–300 (1995).
- 587 67. Wickham, H. *et al.* Welcome to the tidyverse. *J. Open Source Softw.* **4**, 1686 (2019).

- 588 68. Cingolani, P. *et al.* A program for annotating and predicting the effects of single  
589 nucleotide polymorphisms, SnpEff: SNPs in the genome of *Drosophila melanogaster*  
590 strain w1118; iso-2; iso-3. *Fly* **6**, 80–92 (2012).
- 591 69. Pettersen, E. F. *et al.* UCSF ChimeraX: Structure visualization for researchers,  
592 educators, and developers. *Protein Sci.* **30**, 70–82 (2021).
- 593 70. Swan, M. K., Johnson, R. E., Prakash, L., Prakash, S. & Aggarwal, A. K. Structural  
594 basis of high-fidelity DNA synthesis by yeast DNA polymerase delta. *Nat. Struct. Mol.*  
595 *Biol.* **16**, 979–986 (2009).

596

## 597 **ACKNOWLEDGEMENTS**

598 Identification of the CMD2 resistance genes was supported by a grant from the Bill & Melinda  
599 Gates Foundation to ETH Zurich (Investment INV-008213), funding from ETH Zurich and the  
600 Donald Danforth Plant Science Center, Institute for International Crop Improvement. W.G. is  
601 supported by a Yushan Scholarship of the Ministry of Education in Taiwan. We thank Joel Kuon  
602 (ETH Zurich) for initial investigation of the cassava CMD2 locus and Emily McCallum (ETH  
603 Zurich) for Sanger sequencing of genes in the CMD2 region, and the high throughput  
604 sequencing team at the Functional Genomics Center Zurich for Illumina sequencing. We also  
605 thank Irene Zurkirchen (ETH Zurich) for greenhouse propagation and maintenance of the  
606 cassava plants, Justin Villmer, Jennifer Winch and Claire Albin (DDPSC) for plant regeneration,  
607 propagation, greenhouse care and virus inoculations, and Douglas Miano, Catherine Taracha,  
608 Paul Kuria and Theresia Munga (Kenyan Agriculture and Livestock Research Organization,  
609 Kenya) for production of F<sub>1</sub> progeny lines in Kenya.

610

## 611 **AUTHOR CONTRIBUTIONS**

612 Y.W.L. contributed to the WGS-GVA that led to the identification of MePOLD1 resistance  
613 alleles, designed the VIGS experiments, analysed data and co-wrote the manuscript. B.M.  
614 designed and performed the rough and fine mapping, the transcriptomics, analysed data and  
615 co-wrote the manuscript. P.S. conceived, designed, and performed the WGS-GVA that led to  
616 the identification of the MePOLD1 resistance alleles, analysed data and co-wrote the  
617 manuscript. K.B.G. designed and performed the analysis of publicly available re-sequencing  
618 and contributed to writing the manuscript. N.N. designed, performed, and analysed


619 greenhouse CMG experiments and RNAseq datasets. Q.W. performed sanger sequencing,  
620 cloned, and sequenced the full length *MePOLD1* cDNA from 5001-Nase14-#41 and  
621 contributed to writing the manuscript. Z.Z. performed the EWAS and contributed to writing  
622 the manuscript. A.B. developed pipelines for and performed analysis of GBS data, SNP calling  
623 and rough mapping. J.G. performed and contributed to the development and analysis of the  
624 KASP fine-mapping markers. G.B. designed, performed, and analysed RNAseq, SPINDLY-VIGS  
625 experiments and contributed to design of field crossing programs. Z.D. L. performed analysis  
626 on all lines with sanger sequencing, analysed data and contributed to writing the manuscript.  
627 W.E. co-designed field phenotyping experiments, performed mapping population and genetic  
628 crossing field experiments, and analysed data. S.F. constructed and sequenced whole genome  
629 bisulfite libraries and assisted in data analysis. W.Q. performed the Illumina read mapping,  
630 variant calling and clustering analysis. C.C. prepared the Illumina sequencing and performed  
631 VIGS experiments. N.E. performed VIGS experiments. G.A. performed field phenotype data  
632 collection from mapping populations, prepared samples for sequencing and contributed to  
633 data analysis. T.A. conceived and co-designed field phenotyping experiments, analysed data  
634 and contributed to writing the manuscript. S.E.J. conceived and designed the methylation  
635 experiments, analysed data, and contributed to writing the paper. N.J.T. conceived and  
636 designed plant tissue culture investigations, co-designed field crossing and CMD resistance  
637 experiments, analysed data and co-wrote the manuscript. W.G. conceived, designed, and  
638 managed the collaborative research project and efforts between groups, contributed to the  
639 design of experiments, analysed, and interpreted data, and co-wrote the manuscript. R.S.B.  
640 conceived and designed experiments, analysed data, coordinated efforts between groups and  
641 co-wrote the manuscript. The authors wish it to be known that Y.W.L., B.M. and P.S. are equal  
642 first authors and that W.G. and R.S.B. are equal last and corresponding authors. For the  
643 purpose of their CVs, they may list their names as first or last author positions.

644


#### 645 **COMPETING INTERESTS**

646 The authors declare no competing interests. All authors agree on the final manuscript and  
647 submission for publication.







**Fig. 1.** CMD2 type cassava varieties lose resistance upon *de novo* morphogenesis. A) Left – TME204-WT CMD2-type plants challenged with cassava mosaic geminivirus remains symptom free. Middle – embryogenic structures arise from tissue culture induced *de novo* morphogenesis. Right – Regenerated plant shows classic mosaic symptoms after virus challenge. B) F1 populations derived from heterozygous resistant parents (NASE14, NASE19, TME14) crossed with susceptible loss-of-CMD2-resistance (LCR) line. Plants were grown and phenotyped in the field in Uganda and scored for disease over two years on a 1-5 disease score. The disease rating distribution across all populations segregates at 1:1.  $\chi^2 = 0.59$  (C) In each population, ~15% of lines with consistent phenotypes over the two years were selected for bulk segregant analysis (BSA) mapping (solid circles).



**Fig. 2.** Whole genome sequencing and genome variant analysis (WGS-GVA) and fine mapping reveal nonsynonymous SNPs in MePOLD1 that segregate with resistance. A) TME204-WT and F1 progeny, TME419 WT, 60444 WT and TME204, TME419 and 60444 plants regenerated from tissue culture were tested for resistance and susceptibility. TME204 WT, F1-3, F1-7, F1-8, and TME419-WT plants had CMD2 resistance while all other plants were susceptible to ACMV infections. The resistance phenotype is indicated on the left bar (Red – Resistant; Blue – Susceptible). A haplotype-restricted G to C transversion in the MePOLD1 gene at location 9,081,215 bp causes a heterozygous V528L mutation in MePOLD1. Two large ( $n \approx 1,000$ ) F1 mapping populations derived from NASE14  $\times$  TME204-LCR were used to fine map CMD2 (B-E). B) An *in silico* bulk segregant approach was performed using the field phenotyping and genotyping by sequencing (GBS) data (Fig. 1c). The tricube-smoothed allele frequency enrichment ( $\Delta$ SNP-index) across the TME204 hap1 assembly. In C and D the red line denotes the 95% confidence interval. The highlighted region on Chr12 defines the significantly linked CMD2 region. C) Enlargement of the CMD2 locus mapping results. Each point represents a SNP and its corresponding  $\Delta$ SNP-index. The dashed lines indicate the borders of the mapped locus between ~5-13Mb. The previously reported associated marker from Rabbi et al., 2020 is indicated by black arrow. D) Examining the GBS SNP data from individual recombinants within the locus improves the mapping resolution to ~300 kb. Genotypes are extended downstream until the next SNP called. Two non-recombinant homozygous resistant and susceptible lines are added as a control (top and bottom). Based on the location of the mapped locus, and the previously identified GWAS marker, KASP markers (M1-8) were developed for fine mapping (positions denoted by dot-dash lines in C and D). E) A second fine mapping population was phenotyped in the greenhouse using a virus induced gene silencing-based infection assay. Recombinants within the region place CMD2 in the 190Kb interval between markers M3 and M7. Lines P1581 and P1561 are non-recombinant susceptible and resistant controls, respectively. In C and E the genotype at each SNP or marker is indicated by the color (Allele 1, Red, linked to Resistance; Allele 2, Blue, linked to Susceptibility). The resistance phenotype is indicated on the left bar as above. F) Genomic rearrangements within the fine mapped CMD2 locus introduce new gene candidates.



**Fig. 3.** VIGS silencing of *MePOLD1*. CMD-susceptible cassava 60444 recovers from ACMV infection when *MePOLD1* is downregulated by VIGS. (a) Percentage of symptomatic 60444 plants and (b) CMD symptom severity (Fauquet and Fargette, 1990) 18 weeks post-inoculation: ACMV (n = 15), *GUS*-VIGS (n = 30), *MePOLD1*-VIGS (n = 40), and Mock (n = 15). Bars show standard error. (c) Quantification of ACMV titre post-onset of CMD symptoms after inoculation with ACMV (n = 3), *GUS*-VIGS (n = 10), *MePOLD1*-VIGS (n = 10), and Mock (n = 3) (Mann-Whitney U test, \*\*\* = P < 0.001). Week 0 is the first onset of symptoms detected on individual plants. (d) CMD symptoms on cassava leaves after ACMV-VIGS inoculation of 60444 plants with week 0 being when first symptoms were detected on individual plants.



**Fig. 4.** Nonsynonymous SNPs in MePOLD1. (a) Dendrogram of *Manihot esculenta* cultivars analyzed by whole genome sequencing. Non-synonymous SNPs (nsSNPs) in MePOLD1 of various cultivars segregate with CMD2 resistance. Names of resistant cultivars are in blue and harbor either the V528L (cyan), G680V (orange), or L685F (blue) mutation. (b) Average CMD severity across a diverse set of cassava cultivars from the HapMapII population (Ramu *et al.*, 2017) that have either one of the three mutations from (a) or an unknown nsSNP in MePOLD1 ("Other"). (c) Identity of all nsSNPs in MePOLD1 of varieties from the "Other" category in (b). Varieties are split by CMD severity score, where less than 2 and above 2 are resistant and susceptible, respectively. In green are the nsSNPs found only in cultivars with CMD severity scores below 2; all other nsSNPs are in gray. (d) Three-dimensional structure of *S. cerevisiae* POLD1 (PDB: 3IAY) with corresponding MePOLD1 mutations highlighted; V528L in cyan, G680V in orange, and L685F in blue. Additional residues identified in (c), L685F and L598W, are in green. Residue name and position in ScPOLD1 are noted and the corresponding information for MePOLD1 is in parentheses. POLD1 functional domains, N-terminal (beige), exonuclease (grey), and structural motifs of the polymerase domain, palm (pink), fingers (white), and thumb (blue), are highlighted. (e) Zoomed in view of the 3D structure centered on the mutated residues found in MePOLD1.